Home  |  Contact
Due to scheduled maintenance work, this service will not be available from Tuesday August 23rd 06:00 pm until Wednesday August 24th 08:00 am CEST. Apologies for the inconvenience.

UniProtKB/Swiss-Prot Q13797: Variant p.Gly507Glu

Integrin alpha-9
Gene: ITGA9
Variant information

Variant position:  507
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LB/B
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Glycine (G) to Glutamate (E) at position 507 (G507E, p.Gly507Glu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to medium size and acidic (E)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  507
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1035
The length of the canonical sequence.

Location on the sequence:   QPVNCLNVTTCFSFHGKHVP  G EIGLNYVLMADVAKKEKGQM
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         QPVNCLNVTTCFSFHGKHVPGEIGLNYVLMADVAKKEKGQM

Mouse                         QPVNCLNVTVCFRFHGKNVPGEIGLNYNLTADVAQKEKGQL

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 30 – 1035 Integrin alpha-9
Topological domain 30 – 981 Extracellular
Glycosylation 493 – 493 N-linked (GlcNAc...) asparagine
Disulfide bond 497 – 555


Literature citations

Aberrant upregulation of a novel integrin alpha subunit gene at 3p21.3 in small cell lung cancer.
Hibi K.; Yamakawa K.; Ueda R.; Horio Y.; Murata Y.; Tamari M.; Uchida K.; Takahashi T.; Nakamura Y.; Takahashi T.;
Oncogene 9:611-619(1994)
Cited for: NUCLEOTIDE SEQUENCE [MRNA]; VARIANT GLU-507; TISSUE SPECIFICITY; INDUCTION;

Sequence and tissue distribution of the integrin alpha 9 subunit, a novel partner of beta 1 that is widely distributed in epithelia and muscle.
Palmer E.L.; Rueegg C.; Ferrando R.; Pytela R.; Sheppard D.;
J. Cell Biol. 123:1289-1297(1993)
Cited for: NUCLEOTIDE SEQUENCE [MRNA] OF 36-1035; PROTEIN SEQUENCE OF 30-35; VARIANT GLU-507; TISSUE SPECIFICITY;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.